Rufinamide Tablets News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Alembic Pharmaceuticals and Aurobindo Pharma are recalling products in the US due to manufacturing problems. Alembic is recalling 82,400 bottles of Tobramycin Ophthalmic Solution due to “Failed Impurities/Degradation Specifications.” Meanwhile, Aurobindo Pharma is recalling 48 bottles of Rufinamide Tablets, in both 200 mg and 400 mg doses, due to cGMP (current good manufacturing practice) deviations, USFDA said. The batch was released prior to approval. Rufinamide tablets are used to treat seizure disorders.

Global pharma major Lupin Limited today announced the launch of Rufinamide Tablets USP, 200 mg and 400 mg, to market a generic equivalent of Banzel® Tablets, 200 mg and 400 mg, of Eisai Inc.

The key barometers hovered near the flat line in early afternoon trade. Metal shares tumbled while autos and FMCG shares bucked weak market trend. At 12:20 IST, the barometer index, the S&P BSE Sensex, rose 6.05 points or 0.01% at 51,943.49. The Nifty 50 index lost 15.25 points or 0.10% at 15,567.55. The Nifty pared losses after hitting the day's low of 15,528.30 in early afternoon trade. In the broader market, the S&P BSE Mid-Cap index fell 0.39% while the S&P BSE Small-Cap index slipped 0.51%. The market breadth was weak. On the BSE, 1,112 shares rose and 1,857 shares fell. A total of 124...

Glenmark Pharmaceuticals (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel1 Tablets, 200 mg and 400 mg of Eisai, Inc. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for Rufinamide Tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval on 16 May 2016. According to IQVIATM sales data for the 12 month period ending April 2021, the Banzel Tablets, 200 mg and 400 mg market achieved annual sales of approximately $285.3 million. Powered by Capital Market - Live News (T...

Read more about Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg on Business Standard. The medicines are a therapeutic equivalent of Banzel®